Update shared on04 Sep 2025
Following stronger-than-expected Q2 results, raised guidance, and increased optimism about future earnings growth, analysts maintained Zimmer Biomet Holdings’ consensus price target at $110.92.
Analyst Commentary
- Increased confidence in Zimmer Biomet’s second half performance following solid Q2 results.
- Q2 adjusted EPS exceeded consensus estimates, demonstrating stronger than expected operational execution.
- Management raised guidance for the remainder of the year, signaling optimism in future growth.
- Bullish analysts raised their 2026 EPS forecasts, reflecting expectations of sustained earnings momentum.
- Bullish analysts raised price targets to reflect improved outlook and robust earnings trajectory.
What's in the News
- Completed buyback program with 9,071,182 shares repurchased (4.46%) for $979.78 million; no shares repurchased in the latest quarter.
- Revised 2025 full-year revenue growth guidance to 6.7%-7.7% from prior range of 5.7%-8.2%.
Valuation Changes
Summary of Valuation Changes for Zimmer Biomet Holdings
- The Consensus Analyst Price Target remained effectively unchanged, at $110.92.
- The Consensus Revenue Growth forecasts for Zimmer Biomet Holdings remained effectively unchanged, at 5.5% per annum.
- The Discount Rate for Zimmer Biomet Holdings remained effectively unchanged, at 8.30%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.